What is the recommended emergency department management protocol for a patient presenting with status epilepticus?

Status Epilepticus Emergency Department Management

Immediate First-Line Treatment (0-5 Minutes)

Administer IV lorazepam 4 mg at 2 mg/min immediately for any actively seizing patient—this terminates status epilepticus in 65% of cases and is superior to diazepam. 1, 2

Before giving any benzodiazepine:

• Have airway equipment (bag-valve-mask, intubation set) immediately available because respiratory depression requiring intervention is predictable 1, 2
• Start high-flow oxygen and continuous pulse oximetry 1
• Check fingerstick glucose immediately and correct hypoglycemia if present 1

If IV access is unavailable or delayed:

• IM midazolam 10 mg provides equivalent efficacy to IV lorazepam 1
• Intranasal midazolam is an acceptable alternative 1, 2
• Rectal diazepam 0.5 mg/kg if other routes fail 1, 2
• Never use IM diazepam—absorption is erratic; use rectal route instead 1

Lorazepam may be repeated once after at least 1 minute if seizures continue, maximum 2 total doses. 1

---

Second-Line Treatment (5-20 Minutes After Benzodiazepines)

If seizures persist after adequate benzodiazepine dosing, immediately escalate to one second-line agent without delay. 1, 2, 3

The 2019 ESETT trial demonstrated that levetiracetam, fosphenytoin, and valproate have statistically similar efficacy (45-47% seizure cessation), so agent selection should prioritize safety profile and contraindications rather than efficacy alone. 1

Valproate (Preferred for Most Patients)

• Dose: 20-30 mg/kg IV (maximum 3000 mg) over 5-20 minutes 1, 2, 3
• Efficacy: 88% seizure control 1, 2, 3
• Hypotension risk: 0% 1, 2, 3
• Advantage: Superior safety profile compared to phenytoin—no cardiac monitoring required 1
• Absolute contraindication: Women of childbearing potential due to teratogenicity 1, 3

Levetiracetam (Excellent Alternative)

• Dose: 30 mg/kg IV (maximum 2500-3000 mg) over 5 minutes 1, 2, 3
• Efficacy: 68-73% seizure control 1, 2, 3
• Hypotension risk: ~0.7% 1
• Intubation rate: 20% 1
• Advantage: Minimal cardiovascular effects, no cardiac monitoring required, safe in elderly 1, 2

Fosphenytoin (Traditional Option)

• Dose: 20 mg PE/kg IV at maximum rate of 150 PE/min 1, 2, 3
• Efficacy: 84% seizure control 1, 2, 3
• Hypotension risk: 12% 1, 2, 3
• Intubation rate: 26.4% 1
• Requirement: Continuous ECG and blood pressure monitoring mandatory 1, 2

Phenobarbital (Reserve Option)

• Dose: 20 mg/kg IV over 10 minutes (maximum 1000 mg) 1, 2, 3
• Efficacy: 58.2% as initial second-line agent 1, 2, 3
• Disadvantage: Higher risk of respiratory depression and hypotension due to vasodilatory and cardiodepressant effects 1, 2

---

Simultaneous Evaluation for Reversible Causes

While administering anticonvulsants, immediately search for and treat underlying causes—do not delay treatment to obtain neuroimaging. 1, 2, 3

Critical reversible causes to evaluate:

• Hypoglycemia (most rapidly reversible) 1, 2
• Hyponatremia (most common electrolyte disturbance causing seizures) 1, 2
• Hypoxia 1, 2
• Drug toxicity or withdrawal (alcohol, benzodiazepines, barbiturates) 1, 2
• CNS infection 1, 2
• Ischemic stroke or intracerebral hemorrhage 1, 2

---

Refractory Status Epilepticus (≥20 Minutes)

Refractory SE is defined as ongoing seizures despite adequate benzodiazepines AND failure of one second-line agent. 1, 2, 3

At this stage:

• Initiate continuous EEG monitoring immediately 1, 2, 3
• Transfer to ICU for advanced management 1, 4
• Prepare for mechanical ventilation 1, 2

Third-Line Anesthetic Agents

Midazolam Infusion (First Choice)

• Loading dose: 0.15-0.20 mg/kg IV 1, 2, 3
• Maintenance: Start at 1 mg/kg/min, titrate up by 1 mg/kg/min every 15 minutes to maximum 5 mg/kg/min 1, 2, 3
• Efficacy: 80% seizure control 1, 2, 3
• Hypotension risk: 30% 1, 2, 3
• Critical action: Load with a long-acting anticonvulsant (phenytoin/fosphenytoin, valproate, levetiracetam, or phenobarbital) during the infusion before tapering midazolam 1

Propofol (Alternative for Intubated Patients)

• Loading dose: 2 mg/kg IV bolus 1, 2, 3
• Maintenance: 3-7 mg/kg/hour infusion 1, 2, 3
• Efficacy: 73% seizure control 1, 2, 3
• Hypotension risk: 42% 1, 2, 3
• Advantage: Shorter ventilation duration than barbiturates (4 days vs 14 days) 1, 2
• Requirement: Mechanical ventilation mandatory 1, 2

Pentobarbital (Highest Efficacy, Highest Complication Rate)

• Loading dose: 13 mg/kg IV 1, 2
• Maintenance: 2-3 mg/kg/hour infusion 1, 2
• Efficacy: 92% seizure control 1, 2
• Hypotension risk: 77% requiring vasopressor support 1, 2
• Disadvantage: Mean mechanical ventilation duration 14 days 1, 2

EEG monitoring should guide titration to achieve seizure suppression in all refractory cases. 1, 2, 3

---

Critical Pitfalls to Avoid

• Never use neuromuscular blockers alone—they only mask motor manifestations while allowing continued electrical seizure activity and brain injury 1, 3
• Do not skip to third-line agents until benzodiazepines and a second-line agent have been tried 1, 3
• Do not delay anticonvulsant administration for neuroimaging in active status epilepticus 1, 2
• Continuous vital sign monitoring is essential, particularly respiratory status and blood pressure 1, 2, 3
• Be prepared for respiratory support regardless of administration route 1, 2, 3

---

Prognosis

Overall mortality for status epilepticus ranges from 5-22%, increasing dramatically to approximately 65% in refractory cases. 1, 4 Mortality is primarily related to increasing age, underlying etiology, medical comorbidities, and refractoriness of treatment. 4